AxoGen, the Healthcare sector company, was revisited by a Wall Street analyst on August 25. Analyst Mike Kratky from Leerink Partners maintained a Buy rating on the stock and has a $22.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mike Kratky has given his Buy rating due to a combination of factors surrounding AxoGen’s regulatory developments and market potential. The recent delay in the PDUFA date for the Avance Nerve Graft BLA is seen primarily as a procedural matter, despite introducing some uncertainty. The extension was due to the submission of significant new manufacturing and facility data, which the FDA needs additional time to review.
Despite the delay, Kratky acknowledges that the FDA’s anticipated feedback on product labeling aligns with standard review procedures, suggesting a positive outlook for eventual approval. Furthermore, AxoGen’s management has not revised its 2025 guidance, indicating confidence in their projections. These elements contribute to Kratky’s optimistic view on AxoGen’s stock, supporting his Buy rating.
In another report released on August 26, Lake Street also reiterated a Buy rating on the stock with a $30.00 price target.
AXGN’s price has also changed moderately for the past six months – from $20.110 to $14.790, which is a -26.45% drop .